Acer Therapeutics' Debt - II Round

Acer Therapeutics raised a round of funding on April 05, 2017.

Acer Therapeutics is developing the first pharmaceutical therapy for patients with Maple Syrup Urine Disease (MSUD). MSUD is a devastating genetic disease – an inborn error of amino acid metabolism.…

Articles about Acer Therapeutics' Debt - II Round: